Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L18	562	(544/368).CCLS.	US-PGPUB; USPAT	OR	OFF	2006/02/03 19:04
L19	241	trifluoromethylbenzoxazol$	US-PGPUB; USPAT	OR	OFF	2006/02/03 19:04
L20	2	l18 and l19	US-PGPUB; USPAT	OR	OFF	2006/02/03 19:04

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L12	848	((564/214) or (564/442)).CCLS.	US-PGPUB; USPAT	OR	OFF	2006/02/03 18:52
L13	6285	bis adj trifluoromethyl	US-PGPUB; USPAT	OR	OFF	2006/02/03 18:53
L14	19	l12 and l13	US-PGPUB; USPAT	OR	OFF	2006/02/03 18:55

C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10763241-B.str

Part II





chain nodes :
7 8 9 10 11 13 14 15 16 17 18 24 25 28
ring nodes :
1 2 3 4 5 6
chain bonds :
5-7 7-24 8-9 8-10 13-14 13-15 14-16 14-17 14-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
5-7 7-24 8-9 8-10 13-15
exact bonds :
13-14 14-16 14-17 14-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,[*1]

G2:Si,[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:CLASS 18:CLASS 22:CLASS 24:CLASS 25:CLASS 28:CLASS



chain nodes :
7 8 9 10 11 13 14 15 16 17 18 24 25 28
ring nodes :
1 2 3 4 5 6
chain bonds :
5-7 7-24 8-9 8-10 13-14 13-15 14-16 14-17 14-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
5-7 7-24 8-9 8-10 13-15
exact bonds :
13-14 14-16 14-17 14-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,[*1]

G2:Si,[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
22:CLASS 24:CLASS 25:CLASS 28:CLASS

```
L10     STRUCTURE UPLOADED

=> que L10 NOT L9

L11  QUE L10 NOT L9

=> s l11
SAMPLE SEARCH INITIATED 17:29:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      371 TO ITERATE

100.0% PROCESSED      371 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          6265 TO     8575
PROJECTED ANSWERS:                4 TO      200

L12          4 SEA SSS SAM L10 NOT L9

=> s l11 sss full
FULL SEARCH INITIATED 17:29:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     8366 TO ITERATE

100.0% PROCESSED     8366 ITERATIONS                              92 ANSWERS
SEARCH TIME: 00.00.01

L13          92 SEA SSS FUL L10 NOT L9

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   201.34     201.97

FILE 'CAPLUS' ENTERED AT 17:29:57 ON 03 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 3 Feb 2006  VOL 144 ISS 7
FILE LAST UPDATED: 2 Feb 2006  (20060202/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
```

=> s l13
L14 34 L13

=> d l14 1-34 bib abs hitstr

L14 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1078255 CAPLUS
DN 143:346930
TI Preparation of amides as ion-channel ligands for preventing and/or treating pain and inflammation-related conditions
IN Kelly, Michael G.
PA Renovis, Inc., USA
SO U.S. Pat. Appl. Publ., 92 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005222200	A1	20051006	US 2004-961483	20041007
PRAI US 2003-961483P	P	20031007		

OS MARPAT 143:346930
GI



I



II

AB The title compds. I [A = N, CR4, a carbon atom bound to L, or is not an atom; one of W, Z, B, Y and X = a carbon atom bound to L if A is not an atom, another of W, Z, B, Y and X = a carbon atom bound to G, and each of the remaining W, Z, B, Y and X = N or CR4; L = (un)substituted C-C, CR5:CR6 or C.tplbond.C; G = C:O, C;S or SO2; R1 = (un)substituted alkyl, aryl, heteroaryl, etc.; R2 = H, (un)substituted alkyl; R3 = (un)substituted alkyl, aryl, heteroaryl, etc.; each R4 = H, (un)substituted alkyl, acyl, etc.; R5, R6 = H, halo, alkyl, etc.] which may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others, were prepd. and formulated. The general procedures for synthesis of compds. I by amidation of substituted benzoic acid with the corresponding amine, or using automated parallel synthesis method, were described. Over 400 compds. I were prepd. Representative compds. I were tested for inhibition of calcium ion influx induced by capsaicin stimulation. Thus, compd. II showed 75% or greater

inhibition of calcium ion influx induced by capsaicin stimulation. The pharmaceutical compn. comprising the compd. I is disclosed.

IT **852209-81-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amides as the VR1 ion-channel ligands for preventing and/or treating pain and inflammation-related conditions)

RN 852209-81-5 CAPLUS

CN Benzamide, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[(1E)-3,3,3-trifluoro-1-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:962215 CAPLUS

DN 143:248148

TI Preparation of trifluoromethylphenyl-substituted acetic acid derivatives for treating inflammation and metabolic disorders

IN Zhao, Zuchun; Chen, Xin; Wang, Jianchao; Sun, Hongbin; Liang, Jack Shih-Chieh

PA Metabolex, Inc., USA

SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005080340	A1	20050901	WO 2005-US5130	20050217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005222213	A1	20051006	US 2005-61302	20050217

PRAI US 2004-545850P P 20040218
OS MARPAT 143:248148
GI



I



II

AB Title compds. I [wherein X = O, S, NH; Y = CH2OH, COOH; R1, R3 = halo, OH, alk(en/yn)yl; R2 = H, NO2; Q = CH or N; m = 0-3; p = 0-2; etc., and pharmaceutically acceptable salts and prodrugs thereof] were prepd. For example, esterification of 3-CF3C6H4CH2COOH with SOCl2/EtOH followed by BPO-catalyzed .alpha.-bromination with NBS gave bromide 3-CF3C6H4CH(Br)COOEt, which was condensed with 4-CF3C6H4OH prior to basic hydrolysis to afford acetic acid II. Resoln. of this racemate by chiral HPLC or by selective crystn. with chiral amines led to two enantiomers. II and its enantiomers were found to be effective for glucose lowering at the dose of .ltoreq. 125 mg/kg in mice. Therefore, I and pharmaceutical compns. thereof are useful for the treatment of inflammation and metabolic disorders such as diabetes.

IT **863423-06-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of trifluoromethylphenyl-substituted acetic acid derivs. for treating inflammation and metabolic disorders)

RN 863423-06-7 CAPLUS

CN Benzeneacetic acid, .alpha.-[4-[(trifluoroacetyl)amino]-2-(trifluoromethyl)phenoxy]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:902613 CAPLUS
DN 143:248160
TI Preparation of benzamides for promoting apoptosis
IN Bajji, Ashok C.; Arranz, Esther; Srinlvasan, Jayasree M.; Delmar, Eric; Slade, Rachel; Willardsen, Jon Adam
PA Myriad Genetics, Incorporated, USA
SO U.S. Pat. Appl. Publ., 121 pp., Cont.-in-part of Appl. No. PCT/US03/22183.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005187300	A1	20050825	US 2005-39275	20050118
	WO 2004006858	A2	20040122	WO 2003-US22183	20030715
	WO 2004006858	A3	20040429		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 2002-396266P	P	20020715
	US 2002-396773P	P	20020716
	WO 2003-US22183	A2	20030715

OS MARPAT 143:248160
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Benzamides, e.g. I (R2, R3 = halo, C1-C6-haloalkyl; R4, R5 = C1-C6-alkyl; R6 = H, halo; R7 = halo, C1-C4-haloalkyl) and II [R11, R12, R13, R14, R15, R16, R17, R18 = H, halo, N3, OH, SH, cyano, C1-C6-(halo)(hydroxy)alkyl, C2-C6-alkenyl, C2-C6-alkenyloxy, C2-C6-alkynyloxy, C1-C6-alkylsulfonamide,

carbocycle, heterocyclyl, (hetero)aryl, NR50R51, NR50COR40, CONR50R51, C(:G1)G2R41, etc.; R40 = H, OH, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C2-C6-alkenyloxy, C2-C6-alkynyloxy, C1-C6-alkylthiol; R41 = H, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl; R50, R51 = H, OH, C1-C10-(halo)alkyl, C2-C10-alkenyl, C2-C10-alkynyl, C1-C10-alkoxy, C1-C10-alkylthiol, C2-C10-alkenyloxy, C2-C10-alkynyloxy, C2-C6-hydroxyalkyl,etc.; R19 = H, C1-C6-alkyl; R20 = haloalkyl, C2-C6-alkoxy, C2-C6-alkyl, alkylene-O-R8, alkylene-R8, alkylene(R8R9), alkylene = C1-C6-alkylene, R8, R9 = cycloalkyl, aryl, heterocyclyl, heteroaryl; Z = O, NR21, S, R21 = H, C1-C6-alkyl], were prepd. to promote apoptosis. To illustrate the synthesis, reacting 3-O2NC6H4OH with PhCH2CH2OH gave 3-O2NC6H4OCH2CH2Ph which was reduced to the amine and acylated with 5-chlorosalicylic acid to give benzamide III.

IT **634185-11-8P 648925-26-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzamide derivs. for promoting apoptosis)

RN 634185-11-8 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 648925-26-2 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-[5-(trifluoromethyl)-2-(3,3,3-trifluoropropoxy)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:672882 CAPLUS
DN 143:172898
TI A preparation of [(benzoxazolylthio)ethyl]piperazine derivative, useful as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor
IN Shibuya, Kimiyuki; Miura, Toru
PA Kowa Co., Ltd., Japan

SO U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005165026	A1	20050728	US 2004-763241	20040126
WO 2005070907	A1	20050804	WO 2005-JP1297	20050125

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-763241 A 20040126
GI



I



II



III

AB The invention relates to a prepn. of [(benzoxazolylthio)ethyl]piperazine deriv. (I), useful as acyl CoA cholesterol acyltransferase (ACAT) inhibitor. The above-described compd. has both an inhibitory action on ACAT in the artery wall and remarkably high metabolic resistance in human liver microsomes, and exhibits excellent effects for suppressing lipids

depression in aorta. The invention compd. is useful as a highly effective preventive or remedy for hyperlipidemia and arteriosclerosis with less side effects. Compd. I was prepd. via amination of bromoacetamide deriv. II with di-trifluoroacetate of piperazine deriv. III and subsequent hydrolysis (yields: amination - 91.1%, hydrolysis - 86.6%).

IT **860777-81-7P 860777-83-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of [(benzoxazolylthio)ethyl]piperazine deriv. useful as acyl CoA cholesterol acyltransferase (ACAT) inhibitor)

RN 860777-81-7 CAPLUS
CN Benzenamine, 4-(phenylmethoxy)-2,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 860777-83-9 CAPLUS
CN Acetamide, 2-bromo-N-[4-(phenylmethoxy)-2,6-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:451194 CAPLUS
DN 143:7504
TI Preparation of amides as ion-channel ligands for preventing and/or treating pain and inflammation-related conditions
IN Upasani, Ravindra B.; Kelly, Michael G.; Janagani, Satyanarayana
PA Renovis, Inc., USA
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005046683	A1	20050526	WO 2004-US33163	20041007

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-508884P P 20031007

OS MARPAT 143:7504

GI



I



II

AB The title compds. I [A = N, CR4, a carbon atom bound to L, or is not an atom; one of W, Z, B, Y and X = a carbon atom bound to L if A is not an atom, another of W, Z, B, Y and X = a carbon atom bound to G, and each of the remaining W, Z, B, Y and X = N or CR4; L = (un)substituted C-C, CR5:CR6 or C.tplbond.C; G = C:O, C;S or SO2; R1 = (un)substituted alkyl, aryl, heteroaryl, etc.; R2 = H, (un)substituted alkyl; R3 = (un)substituted alkyl, aryl, heteroaryl, etc.; each R4 = H, (un)substituted alkyl, acyl, etc.; R5, R6 = H, halo, alkyl, etc.] which may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others, were prepd. and formulated. The general procedures for synthesis of compds. I by amidation of substituted benzoic acid with the corresponding amine, or using automated parallel synthesis method, were described. Over 400 compds. I were prepd. Representative compds. I were tested for inhibition of calcium ion influx induced by capsaicin stimulation. Thus, compd. II showed 75% or greater inhibition of calcium ion influx induced by capsaicin stimulation. The pharmaceutical compn. comprising the compd. I is disclosed.

IT **852209-81-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amides as the VR1 ion-channel ligands for preventing and/or treating pain and inflammation-related conditions)

RN 852209-81-5 CAPLUS

CN Benzamide, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-[(1E)-3,3,3-trifluoro-1-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:76258 CAPLUS
DN 142:148826
TI Chromatosis remedies
IN Itai, Akiko; Muto, Susumu
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005007151	A1	20050127	WO 2004-JP10558	20040716

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2003-197807 A 20030716
OS MARPAT 142:148826
GI



I

AB Preventive and/or therapeutic drugs for chromatosis and/or skin cancer, contg. as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts of the same, and hydrates and solvates thereof: (I) wherein X is a connecting group whose main chain has 2 to 5 atoms (which group may be substituted); A is hydrogen or acetyl; E is optionally substituted aryl or optionally substituted heteroaryl; and Z is arene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -X-E (wherein X and E are each as defined above) or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -X-E (wherein X and E are each as defined above).

IT **634185-11-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(trifluoromethylphenylchlorohydroxybenzamide analogs as chromatosis and skin cancer remedies and skin whitening cosmetics)

RN 634185-11-8 CAPLUS

CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:60262 CAPLUS
DN 140:128155
TI Preparation of aryl amides for use in inducing cell apoptosis
IN Bajji, Ashok; Arranz, Esther; Srinivasan, Jayasree; Delmar, Eric
PA Myriad Genetics, Inc, USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004006858	A2	20040122	WO 2003-US22183	20030715
	WO 2004006858	A3	20040429		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2492593	AA	20040122	CA 2003-2492593	20030715
EP 1542699	A2	20050622	EP 2003-764721	20030715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005187300	A1	20050825	US 2005-39275	20050118
NO 2005000795	A	20050412	NO 2005-795	20050215
PRAI US 2002-396266P	P	20020715		
US 2002-396773P	P	20020716		
WO 2003-US22183	W	20030715		

OS MARPAT 140:128155

GI



I



II

AB Title compds. I [Y = C, N; Z = bond, O, S, amino, etc.; R0 = HO, alkoxy, hydroxyalkoxy; NO2, etc.; R1-2 = H, halo, NO2, alkoxy, alkyl, aryl, etc.; R3 = H, halo, alkyl, haloalkyl, etc.; R4 = alkyl, haloalkyl, aryl, alkaryl, cycloalkyl, etc.; R5 = H, alkyl; n, p, q = 0-3] are prepd. For instance, 3-nitrophenol is alkylated with phenethyl alc. (THF, DEAD, PPh3, 0-25.degree.), reduced (EtOH/H2O, SnCl2, 75.degree.) and the corresponding aniline coupled to 5-chlorosalicylic acid (PhMe, (EtO)2PO2OPO(EtO)2, 135.degree.) to give II. II has EC50 = 500 .mu.M in the WST-1 cell proliferation assay. I are useful in inducing cell apoptosis.

IT **634185-11-8P 648925-26-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl amides for use in inducing cell apoptosis)

RN 634185-11-8 CAPLUS

CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 648925-26-2 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-[5-(trifluoromethyl)-2-(3,3,3-trifluoropropoxy)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991345 CAPLUS
DN 140:42216
TI Preparation of phenol or phenyl acetate derivatives for treatment of allergic diseases
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 418 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103665	A1	20031218	WO 2003-JP7120	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2488367	AA	20031218	CA 2003-2488367	20030605
	EP 1514544	A1	20050316	EP 2003-730831	20030605

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI JP 2002-165148 A 20020606
WO 2003-JP7120 W 20030605
OS MARPAT 140:42216
GI



I

AB The title compds. I [wherein X = a connecting group; A = H or acetyl; E = (un)substituted aryl or heteroaryl; ring Z = (un)substituted arene or heteroarene] and pharmaceutically acceptable salts, hydrates, and solvates thereof are prepd. for the treatment of allergic diseases, endometriosis, and/or hysteromyoma (no data). A total of .apprx.500 I including N-phenylhydroxybenzamides (N-phenylsalicylamide), N-heterocyclylhydroxybenzamides, N-phenylhydroxycarbazolecarboxamides, N-phenylhydroxynaphthalenecarboxamides, N-phenylhydroxypyridinecarboxamides, N-phenylhydroxyquinoxalinecarboxamide, and N-phenylhydroxyindolecarboxamide were prepd. The compds. I exhibited inhibitory activities against IgE prodn., cell proliferation, and cell degranulation.

IT **634185-11-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenol or Ph acetate derivs. for treatment of allergic diseases)

RN 634185-11-8 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **258353-01-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of phenol or Ph acetate derivs. for treatment of allergic diseases)

RN 258353-01-4 CAPLUS
CN Benzenamine, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991339 CAPLUS
DN 140:42204
TI Preparation of immunity-related protein kinase inhibitors
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 401 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103658	A1	20031218	WO 2003-JP7130	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2487900	AA	20031218	CA 2003-2487900	20030605
	EP 1510210	A1	20050302	EP 2003-730840	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006019958	A1	20060126	US 2005-515343	20050801
PRAI	JP 2002-164525	A	20020605		
	WO 2003-JP7130	W	20030605		

OS MARPAT 140:42204
GI



I

AB The title compds. I [X is a connecting group whose main chain has 2 to 5 atoms and which may have a substituent; A is hydrogen or acetyl; E is

optionally substituted aryl or optionally substituted heteroaryl; and Z is arene which may have a substituent in addn. to the groups represented by the general formulas O-A (wherein A is as defined above) and X-E (wherein X and E are as defined above) or heteroarene which may have a substituent in addn. to the groups represented by the general formulas O-A (wherein A is as defined above) and X-E (wherein X and E are as defined above)] are prepd. Compds. of this invention in vitro at 1 .mu.g/mL gave 90% to 92.6% inhibition of NF-.kappa.B activation.

IT **634185-11-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of immunity-related protein kinase inhibitors)

RN 634185-11-8 CAPLUS

CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **258353-01-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of immunity-related protein kinase inhibitors)

RN 258353-01-4 CAPLUS

CN Benzenamine, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:991338 CAPLUS

DN 140:42203

TI Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivatives for preventive and/or therapeutic drugs for neurodegenerative diseases and epilepsy

IN Muto, Susumu; Itai, Akiko

PA Institute of Medicinal Molecular Design. Inc., Japan

SO PCT Int. Appl., 278 pp.
CODEN: PIXXD2

DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103657	A1	20031218	WO 2003-JP7128	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2488979	AA	20031218	CA 2003-2488979	20030605
	EP 1555018	A1	20050720	EP 2003-730838	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	JP 2002-169640	A	20020611		
	WO 2003-JP7128	W	20030605		

OS MARPAT 140:42203
GI



I

AB Disclosed are preventive and/or therapeutic drugs for (1) neurodegenerative diseases including Alzheimer's disease and (2) epilepsy, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both [wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused -polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above)]. These compds. I are effective for the prevention and/or treatment of Alzheimer's disease and (2) epilepsy based on the simultaneous inhibition of activated protein 1 (AP-1) and transcription factor NF-.kappa.B activation. The compds. I including N-phenylhydroxybenzamide (N-phenylsalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylsalicylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinoxalinecarboxamide, and N-phenylindolecarboxamide derivs. exhibited the inhibition of (1) TNF-.alpha.-stimulated activation of

NF-.kappa.B in HepG2 cells, (2) TNF-.alpha.-stimulated activation of Hela cells, and (3) the activation of AP-1 in HepG2 cells transfected with MEKK-1 expression plasmid. In an Alzheimer's model animal assay, N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide inhibited the memory formation failure in rats injected with human .beta.-amyloid to the hippocampus.

IT **634185-11-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide preventive and/or therapeutic drugs for Alzheimer's disease and epilepsy)

RN 634185-11-8 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **258353-01-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide preventive and/or therapeutic drugs for Alzheimer's disease and epilepsy)

RN 258353-01-4 CAPLUS
CN Benzenamine, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991336 CAPLUS
DN 140:42202
TI Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivatives as anticancer agents
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 265 pp.

CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003103655	A1	20031218	WO 2003-JP7121	20030605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488974	AA	20031218	CA 2003-2488974	20030605
EP 1535610	A1	20050601	EP 2003-730832	20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006014811	A1	20060119	US 2005-516292	20050705
PRAI JP 2002-168332	A	20020610		
WO 2003-JP7121	W	20030605		

OS MARPAT 140:42202
GI



I

AB Disclosed are drugs for the prevention and/or treatment of cancer, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both [wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused -polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above)]. The compds. I including N-phenylhydroxybenzamide (N-phenylsalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylsalicylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinoxalinecarboxamide, and N-phenylindolecarboxamide derivs. in vitro inhibited the proliferation of Jurkat, MIA PACA-2, RD, HepG2, and A549 human cancer cells. N-[3,5-bis(trifluoromethyl)phenyl]-4-chloro-2-hydroxybenzamide in vitro inhibited the proliferation of B16 melanoma,

HT-1080 fibrosarcoma, NB-1 neuroblastoma, and HMC-1-8 breast cancer cells and in vivo metastasis of B16 melanoma in mice.

IT **634185-11-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivs. as anticancer agents)
RN 634185-11-8 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **258353-01-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivs. as anticancer agents)
RN 258353-01-4 CAPLUS
CN Benzenamine, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991335 CAPLUS
DN 140:42201
TI Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivatives as transcription factor NF-.kappa.B activation inhibitors
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 286 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2003103654	A1	20031218	WO 2003-JP7119	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2489091	AA	20031218	CA 2003-2489091	20030605
	EP 1535609	A1	20050601	EP 2003-730830	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	JP 2002-168924	A	20020610		
	WO 2003-JP7119	W	20030605		
OS	MARPAT 140:42201				

GI



I

AB Disclosed are drugs having an inhibitory activity against transcription factor NF-.kappa.B activation, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both [wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused -polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above)]. Also disclosed are (1) inhibitors against prodn. and release of inflammatory mediators and immunosuppressants and (2) drugs for prevention and/or treatment of chronic articular rheumatism. The compds. I including N-phenylhydroxybenzamide (N-phenylsalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylsalicylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinoxalinecarboxamide, and N-phenylindolecarboxamide derivs. exhibited the inhibition of (1) TNF-.alpha.-stimulated activation of NF-.kappa.B (2) TNF-.alpha.-stimulated prodn. of IL-6, IL-8, and PGE2 in human synoviocyte (RA-pos.) cells, (3) collagen-induced inflammation in mice, (4) myocardial ischemic reperfusion disorder in rats, and (5) proliferation of smooth muscle cells of normal coronary artery blood vessel. Some com. available compds. were selected as NF-.kappa.B

inhibitors (ligands) by virtual screening using a three-dimensional database automated retrieval software based on a protein structure of NF-.kappa.B. The activity of the selected compds. were confirmed by reporter assay for inhibition of TNF-.alpha.-stimulated activation of NF-.kappa.B and an assay for inhibition of NF-.alpha.-stimulated prodn. of inflammatory mediators.

IT **634185-11-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivs. as transcription factor NF-.kappa.B activation inhibitors)

RN 634185-11-8 CAPLUS

CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **258353-01-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivs. as transcription factor NF-.kappa.B activation inhibitors)

RN 258353-01-4 CAPLUS

CN Benzenamine, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:991330 CAPLUS

DN 140:27850

TI Preparation of phenol or phenyl acetate derivatives as therapeutic drugs for prevention or treatment of diabetes and/or diabetes complications

IN Muto, Susumu; Itai, Akiko

PA Institute of Medicinal Molecular Design. Inc., Japan

SO PCT Int. Appl., 396 pp.

CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103648	A1	20031218	WO 2003-JP7131	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2488342	AA	20031218	CA 2003-2488342	20030605
	EP 1510207	A1	20050302	EP 2003-730841	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	JP 2002-164524	A	20020605		
	WO 2003-JP7131	W	20030605		

OS MARPAT 140:27850
GI



I

AB Disclosed are medicines for the prevention and/or treatment of diabetes and/or diabetes complications, contg. as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I) and pharmacol. acceptable salts thereof, and hydrates and solvates of both (wherein X is a connecting group whose main chain has 2 to 5 carbon atoms and which may have a substituent; A is hydrogen or acetyl; E is optionally substituted aryl or optionally substituted heteroaryl; and the ring Z is arene which may have a substituent in addn. to the groups represented by the general formulas: -O-A and -X-E, or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A and -X-E). Also disclosed are medicines possessing insulin-resistance improving, hyperinsulinemia improving, and/or hyperglycemia improving activity. A total of .apprx.500 I including N-phenylhydroxybenzamides (N-phenylsalicylamide), N-heterocyclylhydroxybenzamides, N-phenylhydroxycarbazolecarboxamides, N-phenylhydroxynaphthalenecarboxamides, N-phenylhydroxypyridinecarboxamides, N-phenylhydroxyquinoxalinecarboxamide, and N-phenylhydroxyindolecarboxamide were prepd. The compds. I improve insulin resistance by specifically inhibiting IKK-.beta. (I .kappa.B kinase .beta.).

IT **634185-11-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenol or Ph acetate derivs. as therapeutic drugs for prevention or treatment of diabetes and/or diabetes complications)
RN 634185-11-8 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **258353-01-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of phenol or Ph acetate derivs. as therapeutic drugs for prevention or treatment of diabetes and/or diabetes complications)
RN 258353-01-4 CAPLUS
CN Benzenamine, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991329 CAPLUS
DN 140:27849
TI Preparation of phenol or phenyl acetate derivatives as inhibitors against the activation of activator protein-1 (AP-1) and nuclear factor of activated T-cells (NFAT)
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 401 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003103647	A1	20031218	WO 2003-JP7129	20030605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2487891	AA	20031218	CA 2003-2487891		20030605
EP 1512396	A1	20050309	EP 2003-730839		20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
PRAI JP 2002-164526	A	20020605			
WO 2003-JP7129	W	20030605			

OS MARPAT 140:27849

GI



I

AB Disclosed are medicines for inhibiting the activation of AP-1 or NFAT, contg. as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I) and pharmacol. acceptable salts thereof, and hydrates and solvates of both (wherein X is a connecting group whose main chain has 2 to 5 carbon atoms and which may have a substituent; A is hydrogen or acetyl; E is optionally substituted aryl or optionally substituted heteroaryl; and the ring Z is arene which may have a substituent in addn. to the groups represented by the general formulas: -O-A and -X-E, or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A and -X-E). A total of .apprx.500 I including N-phenylhydroxybenzamides (N-phenylsalicylamide), N-heterocyclylhydroxybenzamides, N-phenylhydroxycarbazolecarboxamides, N-phenylhydroxynaphthalenecarboxamides, N-phenylhydroxypyridinecarboxamides, N-phenylhydroxyquinoxalinecarboxamide, and N-phenylhydroxyindolecarboxamide were prepd. The compds. I can exhibit the inhibitory activity against releasing inflammatory cytokines, inflammatory activity, immunosuppressant activity, and antiallergic activity based on inhibiting the activation of AP-1 or NFAT.

IT **634185-11-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenol or Ph acetate derivs. as inhibitors against activation of activator protein-1 (AP-1) and nuclear factor of activated T-cells (NFAT))

RN 634185-11-8 CAPLUS

CN Benzamide, 5-chloro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **258353-01-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of phenol or Ph acetate derivs. as inhibitors against activation of activator protein-1 (AP-1) and nuclear factor of activated T-cells (NFAT))
RN 258353-01-4 CAPLUS
CN Benzenamine, 2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:487387 CAPLUS
DN 137:63257
TI Preparation of benzamides as inhibitors of production and release of inflammatory cytokines
IN Muto, Susumu; Nagano, Tatsuo; Saotome, Tomomi; Itai, Akiko
PA Institute of Medicinal Molecular Design Inc., Japan
SO PCT Int. Appl., 313 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002049632	A1	20020627	WO 2001-JP11084	20011218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2431083	AA	20020627	CA 2001-2431083	20011218
AU 2002022683	A5	20020701	AU 2002-22683	20011218

EP 1352650 A1 20031015 EP 2001-271124 20011218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004259877 A1 20041223 US 2004-433619 20040219
PRAI JP 2000-383202 A 20001218
WO 2001-JP11084 W 20011218
OS MARPAT 137:63257
GI



I

AB The title compds. I (wherein X is a connecting group; A is hydrogen or acetyl; E is aryl or heteroaryl; and Z is arene or heteroarene) are prepd. In an in vitro test using cells, 5-chloro-2-hydroxy-N-(4-methoxynaphthalen-2-yl)benzamide at 1 .mu.g/mL gave 95.1% inhibition of NF-.kappa.B activation.

IT **2023-57-6P 2414-94-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzamides as inhibitors of prodn. and release of inflammatory cytokines)

RN 2023-57-6 CAPLUS
CN Benzamide, 5-fluoro-2-hydroxy-N-[2-[(6,6,6-trifluorohexyl)oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 2414-94-0 CAPLUS
CN Benzamide, 5-fluoro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:271834 CAPLUS
DN 136:309929
TI Preparation of N-alkoxyalkyl-substituted benzimidazoles and their use against parasitic protozoa.
IN Lieb, Folker; Marhold, Albrecht; Neugebauer, Torsten; Greif, Gisela
PA Bayer A.-G., Germany
SO Ger. Offen., 16 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10049468	A1	20020411	DE 2000-10049468	20001006
	WO 2002030909	A1	20020418	WO 2001-EP11010	20010924
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001091877	A5	20020422	AU 2001-91877	20010924
	EP 1326845	A1	20030716	EP 2001-972078	20010924
	EP 1326845	B1	20051214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001014419	A	20030826	BR 2001-14419	20010924
	JP 2004511471	T2	20040415	JP 2002-534295	20010924
	AT 312825	E	20051215	AT 2001-972078	20010924
	US 2004044055	A1	20040304	US 2003-398295	20030403
PRAI	DE 2000-10049468	A	20001006		
	WO 2001-EP11010	W	20010924		

OS CASREACT 136:309929; MARPAT 136:309929
GI



I



II



III

AB This invention discloses the prepn. of benzimidazoles of the general formula I [wherein: R1 = fluoroalkyl; R2 = H, alkyl; R3 = alkyl; R4 = CF3; and R5 = OCF3]. For example, Raney-Nickel redn. of nitroacetamide II, followed by trifluoroacetic anhydride/trifluoroacetic acid mediated cyclization, and amine alkylation with 1-(chloromethoxy)-2-methylpropane provided benzimidazole III and its N-regioisomer as a 1:1 mixt. in 47% yield. III at 50 ppm gave complete control of Eimeria acervulina, Eimeria maxima and Eimeria tenella. The syntheses of 5 compds. and 8 intermediates are described.

IT **409114-44-9P 409114-49-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of N-alkoxyalkyl-substituted benzimidazoles as antiprotozoal agents)

RN 409114-44-9 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[4-(trifluoromethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409114-49-4 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[4-(trifluoromethoxy)-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:104524 CAPLUS
DN 130:168379
TI Diphenyloxadiazolones and related compounds as potassium channel modulators
IN Romine, Jeffrey L.; Martin, Scott W.; Hewawasam, Piyasena; Meanwell, Nicholas A.; Gribkoff, Valentin K.; Starrett, John E., Jr.
PA Bristol-Myers Squibb Company, USA
SO U.S., 39 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5869509	A	19990209	US 1997-902684	19970730
	US 6077861	A	20000620	US 1998-197887	19981123
	US 6271249	B1	20010807	US 2000-538520	20000329
PRAI	US 1996-22983P	P	19960731		
	US 1997-902684	A3	19970730		
	US 1998-197887	A3	19981123		

OS MARPAT 130:168379
GI



I



II

AB Title compds. I [X = 5-membered heterocycle; R1, R2, R3 = H, halogen, OH, CF3, NO2, (NHCOCH2)pNR6R7; R3 .noteq. H and when R1 and R2 are H, R3 may be imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl, pyridinyl; R4, R5 = H, halogen, CF3, NO2, imidazol-1-yl; m, n, p = 0, 1; R6, R7 = H, alkyl; NR6R7 = N-methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine, imidazolinone] are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels. Thus, 5-chloro-o-anisidine was amidated with 3,5-(F3C)2C6H3COCl, converted to the hydrazone, cyclized, and demethylated to give the oxadiazolone II which showed a >125% increase in BK current at 20 .mu.M.

IT **202822-37-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reaction with hydrazine; prepn. of diphenyloxadiazolones and related compds. as potassium channel modulators)

RN 202822-37-5 CAPLUS

CN Benzamide, N-[2-methoxy-5-(trifluoromethyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:94772 CAPLUS

DN 128:167426

TI Preparation of diphenylazoles and analogs as potassium channel modulators

IN Romine, Jeffrey L.; Martin, Scott W.; Hewawasam, Piyasena; Meanwell, Nicholas A.; Gribkoff, Valentin K.; Starrett, John E., Jr.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 121 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9804135	A1	19980205	WO 1997-US14352	19970730

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	TW 467902	B	20011211	TW 1997-86110006	19970715
	ZA 9706554	A	19990125	ZA 1997-6554	19970723
	AU 9740679	A1	19980220	AU 1997-40679	19970730
	AU 711736	B2	19991021		
	EP 915856	A1	19990519	EP 1997-938316	19970730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9710793	A	19990817	BR 1997-10793	19970730
	CN 1226803	A	19990825	CN 1997-196891	19970730
	CN 1116287	B	20030730		
	NZ 334403	A	20000929	NZ 1997-334403	19970730
	JP 2000516925	T2	20001219	JP 1998-509180	19970730
	RU 2175319	C2	20011027	RU 1999-104179	19970730
	NO 9900428	A	19990129	NO 1999-428	19990129
	KR 2000029735	A	20000525	KR 1999-700839	19990130
PRAI	US 1996-22983P	P	19960731		
	WO 1997-US14352	W	19970730		

OS MARPAT 128:167426

AB HOZ1(CH2)mZ2(CH2)nR [I; R = (un)substituted Ph; Z1 = (un)substituted 1,6-phenylene; Z2 = [(thi)oxo](di or tri)azolediyl] were prepd. Thus, 5,2-Cl(MeO)C6H3NH2 was amidated by 3,5-(F3C)2C6H3COCl and the hydrazone of the product cyclocondensed with carbonyldiimidazole to give, after O-demethylation, I [R = C6H3(CF3)2-3,5, Z1 = 4-Cl-1,6-phenylene, Z2 - -3-oxotriazole-4,5-diyl]. Data for biol. activity of I were given.

IT **202822-37-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of diphenylazoles and analogs as potassium channel modulators)

RN 202822-37-5 CAPLUS

CN Benzamide, N-[2-methoxy-5-(trifluoromethyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:259460 CAPLUS

DN 124:289013

TI Preparation of 4-trifluormethylbenzamides as pesticides for plant and material protection.

IN Kuhnt, Dietmar; Haug, Michael; Jelich, Klaus; Stenzel, Klaus; Dehne, Heinz-Wilhelm; Haensler, Gerd; Wachendorff-Neumann, Ulrike; Erdelen, Christoph; Kugler, Martin; Schrage, Heinrich

PA Bayer A.-G., Germany

SO Ger. Offen., 31 pp.
CODEN: GWXXBX

DT Patent

LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4428380	A1	19960215	DE 1994-4428380	19940811
	WO 9605170	A1	19960222	WO 1995-EP3026	19950731
	W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9533822	A1	19960307	AU 1995-33822	19950731
PRAI	DE 1994-4428380	A	19940811		
	WO 1995-EP3026	W	19950731		

OS MARPAT 124:289013
GI



I



II

AB Title compds. (I; Ar = substituted Ph; with specific exceptions), were prepd. Thus, 2-hydroxy-4-trifluoromethylbenzoic acid and 3-chloro-4-fluoroaniline were refluxed with PCl3 in PhMe to give 68% title compd. (II). Numerous I showed 70-100% activity against Phytophthora infestans on tomato plants.

IT **175872-38-5P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-trifluormethylbenzamides as pesticides for plant and material protection)

RN 175872-38-5 CAPLUS
CN Benzamide, 2-hydroxy-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:813070 CAPLUS
DN 123:222345
TI Chemiluminescent acridinium compounds for assay
IN Kawaguchi, Mamoru; Ishibashi, Kenichiro; Takemura, Shoji
PA Kokusai Shaku Kk, Japan

SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 07167862	A2	19950704	JP 1993-313304	19931214
JP 3325370	B2	20020917		
PRAI JP 1993-313304		19931214		

OS MARPAT 123:222345
AB Disclosed are acridinium-based (MARKUSH shown) chemiluminescent compds. for use as label for assay. In example, benzyl 4-bromobutyrate, 3,5-bis(trifluoromethyl)-4-nitrophenol, 2,6-bis(trifluoromethyl)-4-(3-benzyloxycarbonylpropyloxy)-nitrobenzene, 2,6-bis(trifluoromethyl)-4-(3-benzyloxycarbonylpropyloxy)-aniline, 2,6-bis(trifluoromethyl)-4-(3-benzyloxycarbonylpropyloxy)-phenol, 2,6-bis(trifluoromethyl)-4-(3-benzyloxycarbonylpropyloxy)-Ph acridine-9-carboxylate, 2,6-bis(trifluoromethyl)-4-(3-N-succinimidyloxycarbonylpropyloxy)-Ph acridine-9-carboxylate, and 2,6-bis(trifluoromethyl)-4-(3-benzyloxycarbonylpropyloxy)-Ph N-methyl-acridinium-9-carboxylate were prepd. as labels.
IT **168123-65-7P**
RL: MOA (Modifier or additive use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of acridinium compds. as chemiluminescent label for assay)
RN 168123-65-7 CAPLUS
CN Butanoic acid, 4-[4-amino-3,5-bis(trifluoromethyl)phenoxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:38888 CAPLUS
DN 118:38888
TI N-(Substituted-2-fluorophenyl)- and N-(substituted-2-trifluoromethylphenyl)-1,2,4-triazolo-[1,5-a]pyrimidine-2-sulfonanilides. Synthesis and herbicidal activity
AU Costales, Mark J.; Kleschick, William A.; Gerwick, B. Clifford
CS Res. Lab., DowElanco, Walnut Creek, CA, 94598, USA
SO ACS Symposium Series (1992), 504(Synth. Chem. Agrochem. III), 26-33
CODEN: ACSMC8; ISSN: 0097-6156
DT Journal
LA English
OS CASREACT 118:38888
GI



I

AB A series of novel 2-fluoro and 2-trifluoromethyl-6-substituted anilines were prepd. in a regiospecific manner and reacted with substituted 1,2,4-triazolo[1,5a]pyrimidine-2-sulfonyl chlorides to prep. the title compds. which were evaluated as potential herbicides. Heteroatom directed ortho-lithiation was used to prep. the key aniline intermediates. Details of the synthesis, biol. properties and a brief discussion of the structure-activity relationship are presented. DE-498 N-(2,6-difluorophen;yl)-5-methyl-1,2,4-triazolo[1,5-a]pyrimidine-2-sulfoaamide (I) was prepd. from 2,6-difluoroaniline and the resp. triazolopyrimidinesulfonyl chloride. A metabolite of I was N-(2,6-difluorophenyl)-5-(hydroxymethyl)-1,2,4-triazolo[1,5-a]pyrimidine-2-sulfoanamide.

IT **144851-65-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as reactant for triazolopyrimidinesulfoanilide (herbicide))

RN 144851-65-0 CAPLUS

CN Benzenamine, 2-(2,2,2-trifluoroethoxy)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1991:23460 CAPLUS

DN 114:23460

TI Reactions of trifluoromethyl bromide and related halides. Part 10. Perfluoroalkylation of aromatic compounds induced by sulfur dioxide radical anion precursors

AU Tordeux, Marc; Langlois, Bernard; Wakselman, Claude

CS CERCOA, Thiais, 94320, Fr.

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1990), (8), 2293-9
CODEN: JCPRB4; ISSN: 0300-922X

DT Journal

LA English

OS CASREACT 114:23460

AB Perfluoroalkylation of electron-rich arom. compds. with trifluoromethyl bromide, or long-chain perfluoroalkyl iodides, was performed in the presence of sodium dithionite or Zn-SO2. This alkylation occurred at the ortho and para positions relative to the amino or hydroxy substituent.

Pyrroles were perfluoroalkylated regioselectively at the 2-position. This alkylation is interpreted as a radical arom. substitution; the formation of the perfluoroalkyl radical can be induced by a single-electron transfer from SO2 radical anion to the perfluoroalkyl halide.

IT **106877-19-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 106877-19-4 CAPLUS
CN Benzenamine, 3-methoxy-2,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:186231 CAPLUS
DN 108:186231
TI Perfluoroalkylation of anilines in the presence of zinc and sulfur dioxide
AU Wakselman, Claude; Tordeux, Marc
CS CERCOA, CNRS, Thiais, 94320, Fr.
SO Journal of the Chemical Society, Chemical Communications (1987), (22), 1701-3
CODEN: JCCCAT; ISSN: 0022-4936
DT Journal
LA English
OS CASREACT 108:186231
GI



I

AB Perfluoroalkylation of arylamines with CF3Br under slight pressure in the presence of Zn and SO2 in DMF gave o- and p-trifluoromethyl derivs. Thus, aniline (I; R = R1 = H) gave I (R = CF3, R1 = H; R = H, R1 = CF3) in 36 and 20% yields, resp.

IT **106877-19-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(perfluoroalkylation of)
RN 106877-19-4 CAPLUS
CN Benzenamine, 3-methoxy-2,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:37385 CAPLUS
DN 108:37385
TI Preparation of acylresorcinol ethers as antiallergy and antiinflammatory agents
IN Beck, Andreas; Sallmann, Alfred; Lang, Robert W.; Wenk, Paul
PA Ciba-Geigy A.-G. , Switz.
SO Ger. (East), 32 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 244339	A5	19870401	DD 1985-282080	19851025
PRAI DD 1985-282080		19851025		

OS CASREACT 108:37385
GI



I



II

AB Title compds. I [R1 = alkyl; R2 = fluoroalkyl; R3 = H, halo, alkoxy, CF3; R6 = H, halo, CF3, alkyl, (derivatized) -CO2H; R4, R5, R7 = NHC(O)R8, H, alkyl, alkoxy, halo, CF3; R8 = optionally esterified or amidated carboxy or 5-tetrazolyl; Z = (hydroxy)alkylene optionally contg. an oxygen atom] are prepd. as antiallergy and antiinflammatory agents. A soln. of 3 g tetrazole carboxamide deriv. II in CF3CO2H was refluxed for 1 h (deprotection) and the resulting 1H-tetrazolecarboxamide was converted to the Na salt of I (R1 = Me, R2 = CF3CH2CH2, R3 = H, R4 = Me, R6 = Br, R7 =

H, R5 = tetrazol-5-carboxamido) which had an IC50 of 0.012 .mu.M/L in tests of LTD4 induced contraction of guinea pig ileum. A 12 step prepn. of II is given. One thousand tablets, each contg. 25 mg active substance, were formulated from the triethanolammonium salt of N-[[3-[3-(4-acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)phenoxy)propyloxy]-4-chloro-6-methylphenyl]]oxaminic acid 25, lactose 100.7, starch 7.5, polyethylene glycol 5.0, talc 5.0, Mg stearate 1.8 g, and H2O q.s.

IT **112194-06-6P 112194-09-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiallergy and antiinflammatory agent)

RN 112194-06-6 CAPLUS
CN Acetic acid, [[5-[3-[4-acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)phenoxy]propoxy]-4-chloro-2-(trifluoromethyl)phenyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 112194-09-9 CAPLUS
CN Acetic acid, [[5-[3-[4-acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)phenoxy]propoxy]-4-chloro-2-(trifluoromethyl)phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:21527 CAPLUS
DN 108:21527
TI Preparation of phenylbenzoylureas as insecticides
IN Ehrenfreund, Josef
PA Ciba-Geigy A.-G. , Switz.
SO Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 231152	A2	19870805	EP 1987-810047	19870126
	EP 231152	A3	19881005		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
	DK 8700472	A	19870731	DK 1987-472	19870129
	AU 8768094	A1	19870806	AU 1987-68094	19870129
	ZA 8700642	A	19870930	ZA 1987-642	19870129

	BR 8700397	A	19871215	BR 1987-397	19870129
	JP 62185065	A2	19870813	JP 1987-20350	19870130
PRAI	CH 1986-345	A	19860130		
	CH 1986-4863	A	19861205		

OS MARPAT 108:21527

GI



I

AB Title compds. I (R = C1-4 haloalkyl; R1 = H, halo, Me, Et, OMe, OEt; R2 = halo, OMe; R3 = halo, CF3, R4, R5 = H, halo, CF3) are prepd. for use as insecticides. A Et2O soln. of 3.0 g 2-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-trifluoromethylaniline was treated dropwise with 1.5 g 2,6-difluorobenzoyl isocyanate to give I (R = CF2CHFCF3, R1 = R2 = F, R3 = Cl, R4 = H, R5 = CF3) which at 5% was formulated in a powder contg. 95% talc. The above example of I proved effective against a variety of insects at varying concns.

IT **112004-64-5**
RL: PRP (Properties)
(Hofmann degrdn. of)

RN 112004-64-5 CAPLUS

CN Acetamide, N-[2-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **112004-63-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with difluorobenzoyl isocyanate)

RN 112004-63-4 CAPLUS

CN Benzenamine, 2-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **112004-66-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)
RN 112004-66-7 CAPLUS
CN Benzenamine, 2-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **112004-63-4 112004-66-7 112004-67-8**
112004-68-9 112004-69-0 112004-71-4
112004-72-5 112004-75-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with difluorobenzoyl isocyanate)
RN 112004-63-4 CAPLUS
CN Benzenamine, 2-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 112004-66-7 CAPLUS
CN Benzenamine, 2-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 112004-67-8 CAPLUS
CN Benzenamine, 3-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 112004-68-9 CAPLUS
CN Benzenamine, 2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 112004-69-0 CAPLUS
CN Benzenamine, 2-bromo-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 112004-71-4 CAPLUS
CN Benzenamine, 3,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 112004-72-5 CAPLUS
CN Benzenamine, 5-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 112004-75-8 CAPLUS
CN Benzenamine, 2,3-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **112004-65-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(ring chlorination of)
RN 112004-65-6 CAPLUS
CN Benzenamine, 4-(1,1,2,3,3,3-hexafluoropropoxy)-3-(trifluoromethyl)- (9CI)
(CA INDEX NAME)



L14 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1987:101853 CAPLUS
DN 106:101853
TI Perfluoroalkylation of aromatic derivatives
IN Wakselman, Claude; Tordeux, Marc
PA Rhone-Poulenc Specialites Chimiques, Fr.
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 206951	A2	19861230	EP 1986-420130	19860516
	EP 206951	A3	19870311		
	EP 206951	B1	19900321		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	FR 2582301	A1	19861128	FR 1985-7695	19850522
	FR 2582301	B1	19870710		
	FR 2589147	A1	19870430	FR 1985-15857	19851025
	FR 2589147	B1	19871120		
	AT 51218	E	19900415	AT 1986-420130	19860516
	JP 62026241	A2	19870204	JP 1986-114964	19860521
	JP 02019807	B4	19900507		
	US 4731450	A	19880315	US 1986-865346	19860521
	CA 1252792	A1	19890418	CA 1986-509651	19860521
PRAI	FR 1985-7695	A	19850522		
	FR 1985-15857	A	19851025		
	EP 1986-420130	A	19860516		

OS CASREACT 106:101853; MARPAT 106:101853
AB Perfluoroalkylation of arom. compds. is carried out in aprotic polar solvents in the presence of SO2 and a metal chosen from Zn, Cd, Mg, Mn,

Al, Fe, Sn, or Co. Thus, a DMF soln. contg 40 g C6H6, 40 mL 2-methylpyridine, 5 g Zn, and 20 g NaHSO3 was treated with SO2 at 65.degree. and then with BrCF3 at 7-8 atm over 3 h to give 17% PhCF3.

IT **106877-19-4P**, 2,6-Ditrifluoromethyl-3-methoxyaniline
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by fluoroalkylation)

RN 106877-19-4 CAPLUS

CN Benzenamine, 3-methoxy-2,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1986:552732 CAPLUS

DN 105:152732

TI Formamide oxime derivatives as fungicides and insecticides

IN Hayakawa, Koichi; Nishikawa, Hiroaki; Hashimoto, Akira

PA Nippon Soda Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 61043154	A2	19860301	JP 1984-164854	19840808
PRAI JP 1984-164854		19840808		

GI



I



II

AB The title oximes (I; R = H, Br, Cl, iodo, CF3; R1 = alkyl, alkenyl, alkynyl, etc.; R2 = F, CF3; R3 = alkyl, alkenyl, alkynyl, etc.), effective fungicides at 200 ppm and insecticides at 500 ppm, are prepd. Thus, heating a mixt. of 0.0131 mol II (R4 = NH2) and 0.0263 mol HC(OEt)3 in EtOAc at 70-80.degree. gave 4.5 g II (R4 = N:CHOEt), which was dissolved in MeOH and stirred with 0.0144 mol EtONH2 to give 73.3% I (R = R2 = CF3, R1 = propargyl, R3 = Et).

IT **104450-97-7**
RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, with tri-Et orthoformate)
RN 104450-97-7 CAPLUS
CN Benzenamine, 4-(2-propynyloxy)-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:460433 CAPLUS
DN 105:60433
TI Phenylbenzoylurea derivatives
IN Ehrenfreund, Josef
PA Ciba-Geigy A.-G. , Switz.
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA Czech
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 174274	A1	19860312	EP 1985-810382	19850826
	EP 174274	B1	19881123		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL				
	AT 38829	E	19881215	AT 1985-810382	19850826
	IL 76185	A1	19890815	IL 1985-76185	19850826
	CA 1281741	A1	19910319	CA 1985-489645	19850829
	DK 8503959	A	19860301	DK 1985-3959	19850830
	DK 161196	B	19910610		
	DK 161196	C	19911125		
	AU 8546921	A1	19860306	AU 1985-46921	19850830
	AU 587784	B2	19890831		
	ZA 8506651	A	19860430	ZA 1985-6651	19850830
	ES 546582	A1	19860501	ES 1985-546582	19850830
	BR 8504196	A	19860624	BR 1985-4196	19850830
	JP 61065859	A2	19860404	JP 1985-193003	19850831
	US 5210100	A	19930511	US 1989-427940	19891025
PRAI	CH 1984-4179	A	19840831		
	US 1985-767985	B1	19850821		
	EP 1985-810382	A	19850826		
	US 1989-302052	B1	19890125		

OS MARPAT 105:60433
GI



I

AB The phenylbenzoylurea derivs. I (R = H, halo; R1, R2 = halo) are prepd. by several methods for use as insecticides. Thus, 3-chloro-4-(1,1,2,3,3,3-hexafluoropropyloxy)-5-(trifluoromethyl)acetaminobenzene was refluxed with HCl in EtOH for 16 h, to give the corresponding aniline. This was treated in anhyd. Et2O with 2,6-difluorobenzoyl isocyanate, to give I (R = R1 = F, R2 = Cl) (II). II (12.5 ppm) totally controlled Anthonomus grandis adults on cotton, in pot expts. Some I were also active against Tetranychus (no data).

IT **103447-76-3 103447-78-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of)

RN 103447-76-3 CAPLUS

CN Acetamide, N-[3-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 103447-78-5 CAPLUS

CN Acetamide, N-[3-bromo-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **103447-77-4P 103447-79-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction with difluorobenzoyl isocyanate)

RN 103447-77-4 CAPLUS

CN Benzenamine, 3-chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 103447-79-6 CAPLUS
CN Benzenamine, 3-bromo-4-(1,1,2,3,3,3-hexafluoropropoxy)-5-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



L14 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1980:426100 CAPLUS
DN 93:26100
TI Phenoxybutanes and derivatives
IN Spencer, Homer Kenneth; Graben, Melvin Morris
PA Sandoz-Patent-G.m.b.H., Switz.
SO Ger. Offen., 28 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2930728	A1	19800214	DE 1979-2930728	19790728
	DK 7903270	A	19800208	DK 1979-3270	19790802
	NL 7905976	A	19800211	NL 1979-5976	19790803
	FR 2433010	A1	19800307	FR 1979-19930	19790803
	GB 2028811	A	19800312	GB 1979-27060	19790803
	BE 878110	A1	19800206	BE 1979-196633	19790806
	AU 7949614	A1	19800214	AU 1979-49614	19790806
	ES 483148	A1	19800416	ES 1979-483148	19790806
	BR 7905042	A	19800506	BR 1979-5042	19790806
	ZA 7904085	A	19810325	ZA 1979-4085	19790807
PRAI	US 1978-931752	A	19780807		

GI



I



II

AB Phenoxybutanes I [R, R5 independently = H, C1-4 alkyl, CO2R11 (R11 = H, C1-4 alkyl), R1, R3 independently = H, C1-5 alkyl, F, Cl, Br, OH; R2, R4 independently = H, C1-3 alkyl, R2R4 = bond, O; R6, R9 independently = H, F, Cl, Br, CF3, C1-4 alkyl, thioalkyl, alkoxy, mono-, dialkylamine, alkylsulfonyl or -sulfinyl, NO2, cyano, NH2, R9 addnl. = PhO optionally substituted with 1 or 2 F, Cl, Br, CF3, C1-4 alkyl or alkoxy; R7, R8 independently = H, F, Cl, Br, CF3, C1-4 alkyl, alkoxy, or thioalkyl, NO2; R6R7 or R8R9 on adjacent C atoms = C1-2 alkylenedioxy; R10 = H, F, Cl, Br, CF3, C1-4 alkyl], useful as herbicides (no data), were prepd. Thus, 3-HOC6H4CF3 in DMF contg. KOH was treated slowly with cis-BrCH2CH:CHCH2Br and the mixt. stirred 2 h to give cis-2-butene II.

IT **73875-81-7P 73875-92-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 73875-81-7 CAPLUS

CN Benzenamine, 2-(trifluoromethyl)-4-[4-[3-(trifluoromethyl)phenoxy]butoxy]- (9CI) (CA INDEX NAME)



RN 73875-92-0 CAPLUS

CN Benzenamine, 5-(trifluoromethyl)-2-[4-[3-(trifluoromethyl)phenoxy]butoxy]- (9CI) (CA INDEX NAME)



L14 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1979:203646 CAPLUS

DN 90:203646

TI Anodic oxidation of some anilides in trifluoroacetic acid

AU Hess, Ulrich; Gross, Thomas; Jahn, Brigitte
CS Sekt. Chem., Humboldt-Univ. Berlin, Berlin, Ger. Dem. Rep.
SO Zeitschrift fuer Chemie (1979), 19(1), 25-6
CODEN: ZECEAL; ISSN: 0044-2402
DT Journal
LA German
GI



I



II



III

AB The anodic oxidn. of I (R = MeO) in CF3CO2H-KHF2 yields dimer II as well as III in low yields due to radical stability; little trifluoromethylation was obsd. Electrooxidn. of I (R = NO2) and MeCON(CHMe2)C6H4OMe-o were also studied.
IT **70319-24-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 70319-24-3 CAPLUS
CN Benzamide, N-[5-methoxy-2,4-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1964:454698 CAPLUS
DN 61:54698
OREF 61:9440f-g
TI Trifluoroalkoxy-substituted anilides
IN Stecker, Herbert C.
SO 3 pp.
DT Patent
LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 3142703 19640728 US 19620420
FR 1372456 FR
GB 1039872 GB

AB 3-Trifluoromethyl-6-trifluoroethoxyaniline 47 and 5-fluorosalicylic acid 31 refluxed with PhCl 450, PCl3 12, and AlCl3 1 part gave 5-fluoro-3'-trifluoromethyl-6'-trifluoroethoxysalicylanilide. Other compds. were reportedly prepd. The compds. were mildew-proofing and germicidal agents for fibrous materials.

IT **1959-96-2**, o-Salicylophenetidide, .beta.,.beta.,.beta.-trifluoro-5'-(trifluoromethyl)- **2023-57-6**, m-Salicylotoluidide, .alpha.,.alpha.,.alpha.,5-tetrafluoro-6'-[(6,6,6-trifluorohexyl)oxy]- **2414-94-0**, o-Salicylophenetidide, .beta.,.beta.,.beta.,5-tetrafluoro-5'-(trifluoromethyl)-
(prepn. of)

RN 1959-96-2 CAPLUS

CN o-Salicylophenetidide, .beta.,.beta.,.beta.-trifluoro-5'-(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



RN 2023-57-6 CAPLUS

CN Benzamide, 5-fluoro-2-hydroxy-N-[2-[(6,6,6-trifluorohexyl)oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 2414-94-0 CAPLUS

CN Benzamide, 5-fluoro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1964:454697 CAPLUS
DN 61:54697
OREF 61:9440c-f
TI Catalyst for the production of phthalic anhydride from o-xylene
IN Friedrichsen, Wilhelm; Goehre, Otto
PA Badische Anilin- & Soda-Fabrik A.-G.
SO 3 pp.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1166763		19640402	DE	19620724
	FR 1364418			FR	
PRAI	DE		19620724		

AB A catalyst for the whirl bed oxidn. of o-xylene (I) was prepd. by sintering or melting 30-70 wt.-% Cr2O3 and 70-30 wt.-% V2O5. The oxides, or suitable compds. forming the oxides were mixed, in an oxidizing atm., with starch and NH3 soln. and heated to >600.degree. in O or air. A Cr2O3 content <30% caused clogging in the whirl bed, while >70% Cr2O3 caused inactivity. Promoters, 0.1-20% calcd. on the Cr2O3-V2O5 mixt. may be added. Such are the oxides of K, Ag, Ce, Cu, Fe, Ni, Mn, Co, as well as P2O5, MoO3, WO3 and their salts. The catalyst also may be mixed with a suitable carrier (30-90%). The grain size of the catalyst should be 0.05-0.5 mm., the interior surface 0.5-1.8 m.2/gr., esp. 1.2-1.5 m.2/g., and the diam. of the pores 200-600 A. Oxidn. of I was effected advantageously at 380-450.degree., 0.5-10 sec. retention time. The concn. of I is 30-130 g./m.3 air, favorably with addn. of 0.01-0.1% SO2. Thus, to prep. a catalyst contg. 34% Cr2O3 V2O5 890 and wheat starch 500, were mixed, the mixt. added to (NH4)2 Cr2O7 755 in H2O 1100, concd. NH3 800 (vol.) added as the mixt. became hot and gelled, the mass dried at 60.degree. and broken into 10-30 mm. pieces, these used to fill a vertical quartz tube, O introduced (burning of the starch was started by local heating), and the O stream regulated to obtain a fluid melt, which was drawn off at the lower end of the tube and, after cooling, broken and ground into 0.2-0.5 mm. pieces. The interior surface was 0.6 m.2/g. A quartz tube (1000 .times. 30 mm.) contg. 9 mm. porcelain balls was filled with 150 ml. of the catalyst, heated to 440.degree., and an air stream of 760 l./hr. contg. 49 g. 98% I passed in, which caused the whirl bed to give 43 g. phthalic anhydride and 2.9 g. maleic anhydride per hr. A catalyst prepd. in the same way but with 5% K2O gave 90.4%, with 3% Co oxide 90.6% yield. Without Cr and promotor the yield was 82.7%.

IT **2023-57-6**, m-Salicylotoluidide, .alpha.,.alpha.,.alpha.,5-tetrafluoro-6'-[(6,6,6-trifluorohexyl)oxy]-

(prepn. of)
RN 2023-57-6 CAPLUS
CN Benzamide, 5-fluoro-2-hydroxy-N-[2-[(6,6,6-trifluorohexyl)oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1961:61472 CAPLUS
DN 55:61472
OREF 55:11750f-i,11751a-d
TI Arenesulfonic acid arylamides
PA J. R. Geigy Akt.-Ges.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 859345		19610118	GB	
	CH 361275			CH	
	CH 362688			CH	
	US 3034955		1962	US	

AB To 58.8 parts 2,4,5-trichloroaniline dissolved in 180 parts pyridine, was added dropwise with stirring 93 parts 3-trifluoromethyl-4-chlorobenzenesulfonyl chloride (I) while the temp. was kept below 0.degree.. The mixt. was kept for 8 hrs. at room temp., warmed, kept at 70-5.degree. for 8 hrs. more, and cooled, 200 parts H2O was added, and the soln. was made strongly alk. and distd. with steam. Acidification of the residue pptd. 3-trifluoromethyl-4-chlorobenzenesulfonyl-2',4',5'-trichloroanilide (II), m. 146-8.degree. (CCl4). By using stoichiometrical amts., the following compds. were prepd. similarly (reactants, product, and m.p. given): 2-amino-4-trifluoromethylanisole, 3,4-dichlorobenzenesulfonyl chloride, 3,4-dichlorobenzenesulfonyl-2'-methoxy-5'-trifluoromethylanilide, 100-2.degree.; 2-amino-4-trifluoromethylanisole, I, 3-trifluoromethyl-4-chlorobenzenesulfonyl-2'-methoxy-5'-trifluoromethylanilide, 95-7.degree.; 2-amino-4-chloroanisole, I, 3-trifluoromethyl-4-chlorobenzenesulfonyl-2'-methoxy-5'-chloroanilide, 148-50.degree.; 2-amino-4,5-dichloroanisole, I, 3-trifluoromethyl-4-chlorobenzenesulfonyl-2'-methoxy-4',5'-dichloroanilide, 126-8.degree.; 3,5-bis(trifluoromethyl)aniline, I, 3-trifluoromethyl-4-benzenesulfonyl-3',5'-bis(trifluoromethyl)anilide, 111-13.degree.. To a soln. of 44 parts II in 250 parts H2O and 48 parts 30% NaOH was added dropwise 25 parts Me2SO4. The mixt. was stirred for 3 hrs. at 60-5.degree. and cooled, and the ppt. was filtered, dried, and recrystd. from ligroine to give the N-Me deriv. (III) of II, m. 121-3.degree.. To a soln. of 63 parts 2,4,5-trichloro-N-methylaniline in 100 parts PhNMe2 and 150 parts C6H6 cooled to 5.degree. was added dropwise 93 parts I while the temp. was kept

below 10.degree.. The mixt. was kept for 5 hrs. at room temp. and 8 hrs. at 65-75.degree., cooled, and poured into ice and dild. HCl. The C6H6 layer was removed, washed with H2O, dried, and concd., and the residue was recrystd. from ligroine to give III. To a soln. of 68.7 parts 2,4-dichloro-5-trifluoromethylaniline in 200 parts Me2CO and 150 parts H2O, 93 parts I was added dropwise at 50-5.degree.. Simultaneously 60 parts 15% NaOH was added dropwise to keep the mixt. alk. The mixt. was stirred for 1 hr. at 50.degree., made strongly alk. by adding 30 parts 30% NaOH, distd. with steam, and acidified with HCl. The ppt. was filtered, washed with H2O, dried, and recrystd. from CCl4 to give 3-trifluoromethyl-4-chlorobenzenesulfonyl-2',4'-dichloro-5-trifluoromethylanilide (IV), m. 142-5.degree.. IV (47.2 parts) in 300 parts dioxane and 17 parts 30% NaOH was treated with 16 parts BuBr in 32 parts dioxane dropwise during 5 hrs. at 90.degree.. The mixt. was stirred for 15 hrs. longer at 90.degree., dild. with H2O, made alk., and distd. with steam, the residue was sepd., dried in vacuo, and crystd. from pet. ether to give the N-Bu deriv. (V) of IV as a white powder, m. 96-8.degree.. The following compds. were prepd. similarly (m.p. given): 3,4-dichlorobenzenesulfonyl-2'-trifluoromethyl-4'-chloroanilide, 112-114.degree.; 3-trifluoromethyl-4-chlorobenzenesulfonyl-2'-trifluoromethyl-4'-chloroanilide, 106-8.degree.; 3,4-dichlorobenzenesulfonyl-2',5'-dichloro-4'-trifluoromethylanilide, 139-41.degree.; 3-trifluoromethyl-4-chlorobenzenesulfonyl-2',5'-dichloro-4'-trifluoromethylanilide, 126-8.degree.; 3-trifluoromethyl-4-chlorobenzenesulfonyl-2'-nitro-4'-trifluoromethylanilide, 151-3.degree.; 2,4,5-trichlorobenzenesulfonyl-2'-chloro-5'-trifluoromethylanilide, 106-8.degree.; 3-trifluoromethyl-4-chlorobenzenesulfonyl-2',3',4'-trichloroanilide, 131-3.degree.; 3-trifluoromethyl-4-chlorobenzenesulfonyl-3'-trifluoromethyl-4'-chloroanilide, 143-5.degree.. The compds. are useful as insecticides against textile pests.

IT **1764-28-9**, m-Toluenesulfon-o-anisidide, 4-chloro-.alpha.,.alpha.,.alpha.-trifluoro-5'-(trifluoromethyl)-
(prepn. of)

RN 1764-28-9 CAPLUS

CN m-Toluenesulfon-o-anisidide, 4-chloro-.alpha.,.alpha.,.alpha.-trifluoro-5'-(trifluoromethyl)- (6CI, 8CI) (CA INDEX NAME)



L14 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1955:53531 CAPLUS

DN 49:53531

OREF 49:10286f-i,10287a-b

TI 8-Hydroxy-5-trifluoromethylquinoline

AU Pettit, M. R.; Tatlow, J. C.

CS Univ. Birmingham, UK

SO Journal of the Chemical Society, Abstracts (1954) 3852-4
CODEN: JCSAAZ; ISSN: 0590-9791

DT Journal
LA Unavailable
OS CASREACT 49:53531
AB cf. C.A. 49, 9648e. Two syntheses of the title compd. are described. 4-Chloro-3-nitrobenzotrifluoride (I) (50 g.) in satd. ammoniacal EtOH heated at 120.degree. in an autoclave for 5 hrs. under N, the soln. concd., and the residue recrystd. from aq. EtOH, gave 35.5 g. 4-amino-3-nitrobenzotrifluoride (II), m. 106-7.degree. (trifluoroacetyl deriv., m. 65-6.degree.; Ac deriv., m. 112-13.degree.). II (15 g.) in 4:1 concd. H2SO4-H2O diazotized, the resulting soln. added gradually to a boiling aq. soln. of CuSO4.5H2O with the volatile matter being continuously steam distd., the distillate extd. with Et2O, the ext. dried and evapd., and the residue distd., gave 7.1 g. 4-hydroxy-3-nitrobenzotrifluoride (III), pale yellow, b12 92-4.degree. (p-toluenesulfonate, m. 58-9.degree.). III (0.42 g.) refluxed with aq. 10% NaOH, cooled, and acidified gave 0.28 g. 4-hydroxy-3-nitrobenzoic acid (IV), m. 181-2.degree. (from H2O). IV (1.4 g.) was also formed by refluxing 2.15 g. of I in EtOH with aq. KOH for 15 hrs., evapg., and acidifying. III (6.32 g.) in EtOH with H and Raney Ni at atm. pressure gave 4.92 g. 4-hydroxy-3-aminobenzotrifluoride (V), m. 121-2.degree. (from benzene) (Ac deriv., m. 157-8.degree.). A Skraup reaction on 2.19 g. of V gave 0.7 g. of 8-hydroxy-5-trifluoromethylquinoline (VI), m. 92-6.degree. (from EtOH); vacuum sublimation gave a pale yellow solid, m. 96-7.degree. (p-toluenesulfonate, m. 156.5-7.5.degree.). VI (0.073 g.) in Et2O with CH2N2 gave 0.045 g. 8-Me ether (VII), m. 80.degree.. To 25 g. of 4-methoxy-3-nitrobenzotrifluoride (VIII) in EtOH and concd. HCl were added, with stirring, 100 g. of SnCl2.H2O. After 30 min. reflux, the mixt. was poured into excess aq. NaOH and ice. Extn. with Et2O and evapn. gave 15 g. 4-methoxy-3-aminobenzotrifluoride (IX), m. 58-9.degree. (from petr. ether, b. 60-80.degree.) (trifluoroacetyl deriv., m. 99-101.degree.). Catalytic reduction of VIII (Benkeser and Buting, C.A. 48, 9333e) also gave IX, while incomplete reduction of VIII gave, by fractional crystn. from EtOH, 2,2'-dimethoxy-5,5'-bistrifluoromethylazobenzene, red needles, m. 215-16.degree., and 2,2'-dimethoxy-5,5'-bistrifluoromethylazoxybenzene, pale yellow prisms, m. 133.degree.. A Skraup reaction on 4.85 g. IX gave 1.71 g. VII, m. 81-2.degree. (from EtOH; then from petr. ether, b. 60-80.degree.). VII was unattacked by boiling aq.-alc. KOH, but refluxing with HI for 25 hrs. gave 8-hydroxyquinoline.
IT **7582-79-8**, o-Acetanisidide, 2,2,2-trifluoro-5'-(trifluoromethyl)- (prepn. of)
RN 7582-79-8 CAPLUS
CN o-Acetanisidide, 2,2,2-trifluoro-5'-(trifluoromethyl)- (8CI) (CA INDEX NAME)



```
=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   174.66     376.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -25.50     -25.50

FILE 'CAOLD' ENTERED AT 17:31:07 ON 03 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> s l13
L15           4 L13

=> d l15 1-4 bib hitstr

L15  ANSWER 1 OF 4  CAOLD  COPYRIGHT 2006 ACS on STN
AN   CA61:9440g  CAOLD
TI   quaternary ammonium cyclic imides
AU   Shibe, William J., Jr.; Sittenfield, M.
PA   Hollichem Corp.
DT   Patent
     PATENT NO.     KIND          DATE
     ------------   -----------   ----
PI   US 3133072                   1964
     FR 1384297
IT   2414-94-0
RN   2414-94-0  CAOLD
CN   Benzamide, 5-fluoro-2-hydroxy-N-[2-(2,2,2-trifluoroethoxy)-5-
     (trifluoromethyl)phenyl]- (9CI)  (CA INDEX NAME)
```



L15 ANSWER 2 OF 4 CAOLD COPYRIGHT 2006 ACS on STN
AN CA61:9440f CAOLD
TI trifluoroalkoxy-substituted anilides
AU Stecker, Herbert C.
DT Patent

PATENT NO.	KIND	DATE
US 3142703		1964
FR 1372456		
GB 1039872		

IT **1959-96-2** **2023-57-6**
RN 1959-96-2 CAOLD
CN o-Salicylophenetidide, .beta.,.beta.,.beta.-trifluoro-5'-(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



RN 2023-57-6 CAOLD
CN Benzamide, 5-fluoro-2-hydroxy-N-[2-[(6,6,6-trifluorohexyl)oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 4 CAOLD COPYRIGHT 2006 ACS on STN
AN CA55:11750g CAOLD